@entity715 events in patients with @entity1701 treated with XXXX : a series of eight cases.

@entity1 @entity2067 @entity49 @entity1701 @entity1150 @entity3925 @entity955 @entity715
The current treatment for @entity1701 ( @entity1701 ) with @entity715 manifestation is long-term anticoagulation. @entity2067 antagonists (VKA) are usually the agents of choice. However, VKA limitations, such as unpredictable anticoagulation effects due to interaction with diet and other drugs, require regular monitoring. This may impact on @entity1 ' quality of life. Since the approval of new oral anticoagulants (NOAC) for non-valvular @entity955 and @entity1150 prevention, much has been speculated about its use in @entity1701 @entity1 . We report here a series of eight @entity1701 @entity1 with failure of @entity715 prevention during @entity3925 use. All @entity1 had @entity49 as the initial manifestation of @entity1701 , and two of them also had arterial manifestations. Three @entity1 had triple antibody positivity. Five @entity1 developed arterial events during the treatment with @entity3925 . Until the results of ongoing trials of @entity3925 for @entity1701 are presented, NOAC should not be recommended to @entity1701 @entity1 . Our preliminary experience as well cases previously reported in the literature suggest that there is a high-risk group that is less protected with @entity3925 , namely those with previous arterial @entity715 or triple positivity. VKA remains to be the mainstay treatment for @entity715 .
